Treatment of head and neck cancer with photodynamic therapy: results after one year

AbstractPhotodynamic therapy (PDT) is a new and promising treatment modality for the treatment of malignant disease. This paper reports the preliminary experience of our group in the use of this therapy for the treatment of tumours arising in the head and neck. The majority of treatments in these cases have used a second generation systemic photosensitizer, meta-tetrahydroxyphenylchlorin (m-THPC). Two other cases were treated with either Photofrin 2 (a first generation systemic sensitizer) or with the topical photosensitizer, delta-aminolaevulinic acid (δ-ALA).The initial results have been encouraging with good clinical responses evident in patients presenting with a variety of differing tumour types. We feel there is now sufficient evidence of the efficacy of this treatment to warrant a multicentre prospective study into the treatment of early head and neck cancer with PDT.

Download Full-text

EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

Journal of Controlled Release ◽

10.1016/j.jconrel.2016.03.014 ◽

2016 ◽

Vol 229 ◽

pp. 93-105 ◽

Cited By ~ 65

Author(s):

Pieter B.A.A. van Driel ◽

Martin C. Boonstra ◽

Maxime D. Slooter ◽

Raimond Heukers ◽

Marieke A. Stammes ◽

...

Keyword(s):

Head And Neck Cancer ◽

Photodynamic Therapy ◽

Head And Neck ◽

Neck Cancer ◽

Clinical Model

Download Full-text

Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials

Bionatura ◽

10.21931/rb/2020.05.01.8 ◽

2020 ◽

Vol 5 (1) ◽

pp. 1056-1062

Author(s):

Carmen Viada ◽

Aliz M. Vega ◽

Mayte Robaina ◽

Aliuska Frías ◽

Mabel Álvarez ◽

...

Keyword(s):

Monoclonal Antibody ◽

Sensitivity Analysis ◽

Head And Neck Cancer ◽

Head And Neck ◽

Phase Ii ◽

Neck Cancer ◽

Meta Analysis ◽

Sufficient Evidence ◽

Forest Plot ◽

Controlled Trials

Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: highly expressed protein in malignant tumors of epithelial origin. It has been registered for head and neck tumors since 2002. To determine the effectiveness of Nimotuzumab in head and neck cancer through the combined meta-analysis technique. A search was conducted in PubMed, in an indexed magazine with the words “Nimotuzumab”, “head and neck,” 48 articles published by Cuban and foreign authors were detected between April 1, 2005, and July 31, 2019, in which the results of clinical studies conducted with the monoclonal antibody Nimotuzumab are described. Seven clinical trials conducted in Cuba from 2005-2019 with Nimotuzumab are described; three Phase I / II (with 14, 10 and 10 patients respectively), a Phase II / III with 106 patients, a Phase II with 37 patients, two Phase IV (with 386 and 225 patients each) and a study promoted by the Researcher with 17 patients. From these studies, the three controlled trials were selected by the PRISMA flow chart. The meta-analysis consisted of the construction of the Forest Plot graph, the sensitivity analysis and the cumulative analysis. The meta-analysis shows favorable results for Nimotuzumab, without heterogeneity (I2 = 0%). The sensitivity analysis reveals that the test that differs most from the others is Phase II / III. The cumulative analysis indicates that after the second trial, there is already sufficient evidence.

Download Full-text

Photodynamic Therapy of Head and Neck Cancer — What's Old and What's New

Handbook of Photodynamic Therapy ◽

10.1142/9789814719650_0014 ◽

2016 ◽

pp. 439-458 ◽

Cited By ~ 1

Author(s):

Merrill A. Biel

Keyword(s):

Head And Neck Cancer ◽

Photodynamic Therapy ◽

Head And Neck ◽

Neck Cancer

Download Full-text

Impact on quality of life and sleep in head and neck cancer survivors one year after receiving radiotherapy

10.1183/13993003.congress-2021.pa949 ◽

2021 ◽

Author(s):

Natalia Muñoz Vigueras ◽

Vanessa Gabriela Jerviz Guia ◽

Isabel Castillo Pérez ◽

Paula Obeso Benitez ◽

Javier Martín Núñez ◽

...

Keyword(s):

Quality Of Life ◽

Head And Neck Cancer ◽

Cancer Survivors ◽

Head And Neck ◽

Neck Cancer ◽

One Year

Download Full-text

Outcomes of urgent suspicion of head and neck cancer referrals in Glasgow

Annals of The Royal College of Surgeons of England ◽

10.1308/rcsann.2018.0168 ◽

2019 ◽

Vol 101 (2) ◽

pp. 103-106 ◽

Cited By ~ 3

Author(s):

CM Douglas ◽

V Carswell ◽

J Montgomery

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Neck Cancer ◽

Significant Proportion ◽

Cancer Pathways ◽

Clinic Appointment ◽

Benign Pathology ◽

Primary Care Patients ◽

One Year ◽

The One

Introduction Primary care patients with a suspected head and neck cancer are referred through the urgent suspicion of cancer referral pathway. Rates of cancer detection through this pathway are low. Evidence surrounding the pathway of these patients is lacking. This study aimed to determine the outcome of urgent suspicion of cancer referrals for head and neck cancer. Methods and methods All head and neck cancer urgent suspicion of cancer referrals in NHS Greater Glasgow and Clyde between June 2015 and May 2016 were analysed in regard to their clinical pathway. Results There were 2116 urgent suspicion of cancer referrals in the one-year period. The overall cancer rate was 235 (11.8%), compared with 152 (7.6%) that resulted in a primary head and neck cancer diagnosis. Of the total, 851 (42.6%) were reassured and discharged after one clinic appointment; 536 (26.8%) were followed up for suspected benign pathology and 436 (21.8%) were actively investigated for cancer. Conclusion A significant proportion of patients attending urgent suspicion of cancer clinic appointments can be seen and discharged in one clinic appointment, provided there is same day imaging available. Cancer identification rates through urgent suspicion of cancer pathways remain low.

Download Full-text